<DOC>
	<DOCNO>NCT01493973</DOCNO>
	<brief_summary>Friedreich 's ataxia ( FRDA ) rare genetic disorder characterise severe neurological disability cardiomyopathy . Friedreich 's ataxia consequence frataxin deficiency . Although several drug propose , available treatment . Four trial recently demonstrate erythropoietin increase intracellular level frataxin . The present project aim test long term therapeutic approach use erythropoietin , already available commercialise drug . The study test effect erythropoietin exercise capacity , reduce patient FRDA . Additional objective study drug 's safety tolerability , effect frataxin , blood vessel reactivity , heart functional index , disease progression .</brief_summary>
	<brief_title>Efficacy Study Epoetin Alfa Friedreich Ataxia</brief_title>
	<detailed_description>Friedreich 's ataxia ( FA ) autosomal recessive ataxia cause trinucleotide GAA expansion first intron FXN gene . The gene encode 210aa mitochondrial protein call frataxin , whose mRNA protein level severely reduce FA . It suggest frataxin involve iron-sulphur cluster heme biogenesis , iron binding/storage , chaperone activity . Clinically , age onset generally around puberty , disease progress , increase ataxia limb , eventually patient wheelchair bound twenty . Cardiomyopathy myocardial hypertrophy occurs often predominant cause death . Type II diabetes , scoliosis , foot deformity , optic atrophy , deafness relatively frequent symptom . Erythropoietin ( EPO ) glycoprotein act main regulator erythropoiesis . Evidence suggest EPO receptor express nervous tissue , neuroprotective effect show animal model cerebral ischemic damage . EPO increase frataxin level culture human lymphocyte FRDA patient . However , frataxin protein increase precede mRNA increase , suggest post-transcriptional mechanism involve . To date , four phase II clinical trial publish regard use EPO FRDA patient .</detailed_description>
	<mesh_term>Ataxia</mesh_term>
	<mesh_term>Cerebellar Ataxia</mesh_term>
	<mesh_term>Friedreich Ataxia</mesh_term>
	<mesh_term>Epoetin Alfa</mesh_term>
	<criteria>Molecular diagnosis Friedreich Ataxia Age ≥12 year Body weight ≥30 , ≤90 Kg SARA score ≤30 Patient able read sign inform consent Patients able perform cardiopulmonary test Treatment Erythropoietin previous 12 month Treatment Idebenone Contraindications CPET : cardiac valve disease , ischemic cardiomyopathy , atrial fibrillation , asthma , chronic obstructive pulmonary disease , arrhythmias judge compatible exercise . Any Cardiac and/or Hepatic and/or Renal disease judge clinically relevant investigator Any clinically relevant ECG abnormality may interfere study Any abnormal clinically relevant laboratory exam screen visit may interfere trial Anemia Hemoglobin &lt; 10 g/dL Positive history venous and/or arterial thrombosis Drugresistant arterial hypertension Positive history drugresistant epilepsy Patients treatment allow study drug ( start 3 month prior screen ) Any acute/chronic disease might interfere clinical trial , judge investigator Hypersensitivity Epoetin alfa component study drug Patients able comply study For female patient ( Sexually active , hysterectomized , sterilize , menopause patient exclude follow criterion ) : pregnancy and/or breastfeed and/or inadequate contraception .</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2015</verification_date>
	<keyword>Erythropoietin</keyword>
	<keyword>EPO</keyword>
	<keyword>Friedreich</keyword>
	<keyword>Ataxia</keyword>
	<keyword>Epoetin alfa</keyword>
	<keyword>VO2 max</keyword>
	<keyword>SARA</keyword>
	<keyword>EQ-5D</keyword>
	<keyword>frataxin</keyword>
</DOC>